Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

被引：0
|
作者：
Petrie, Mark
Bain, Stephen
Hoff, Soren Tetens
Johansen, Nicklas
Rasmussen, Soren
Vilsboell, Tina
Husain, Mansoor
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A9392
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina Pettersson
    Rasmussen, Soren
    Bain, Stephen
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [2] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Mansoor Husain
    Agostino Consoli
    Alessandra De Remigis
    Anna Sina Pettersson Meyer
    Søren Rasmussen
    Stephen Bain
    [J]. Cardiovascular Diabetology, 21
  • [3] Effect of semaglutide versus placebo on cardiovascular outcomes by baseline HbA1c: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Mellbin, L. G.
    Bhatt, D. L.
    David, J. -P.
    Petrie, M. C.
    Rasmussen, S.
    Schytz, P. A.
    Vilsboll, T.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S304 - S305
  • [4] SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS REGARDLESS OF METFORMIN USE: A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF SUSTAIN 6 AND PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina
    Rasmussen, Soren
    Bain, Stephen
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1604 - 1604
  • [5] EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 152 - 152
  • [6] Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
    Verma, Subodh
    Fainberg, Udi
    Husain, Mansoor
    Rasmussen, Soren
    Ryden, Lars
    Ripa, Maria Sejersten
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1677 - 1680
  • [7] Semaglutide reduced cardiovascular events regardless of metformin use: a post hoc exploratory subgroup analysis of SUSTAIN 6 and PIONEER
    Husain, M.
    Consoli, A.
    De Remigis, A.
    Meyer, A. S. P.
    Rasmussen, S.
    Bain, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 14 - 14
  • [8] REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 183 - 183
  • [9] Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
    Strain, W. David
    Frenkel, Ofir
    James, Martin A.
    Leiter, Lawrence A.
    Rasmussen, Soren
    Rothwell, Peter M.
    Ripa, Maria Sejersten
    Truelsen, Thomas C.
    Husain, Mansoor
    [J]. STROKE, 2022, 53 (09) : 2749 - 2757
  • [10] SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
    Bellary, S.
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. Gaarsdal
    Leiter, L.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E6 - E7
12345